Stocks Health care MNKD
NASDAQ · Health careMannkind Corp (MNKD)
Mannkind Corp brought in $413.4M of revenue over the twelve months to September 30, 2026, up 31.7% from a year earlier. It posted a net loss of $74.8M. Operating cash flow minus capital spending left $13.7M of free cash flow in fiscal 2025. At September 30, 2026 it held $41.3M in cash against $319.4M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Mannkind Corp
- Net worth
- Mannkind Corp has a market value (market cap) of $1.3B at the latest share price, and shareholders' equity of -$37.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $349M (+22.2% year on year), with net income of $5.9M. Over the 12 months to September 30, 2026: revenue $413.4M, net loss $74.8M.
- Cash flow
- In fiscal 2025 operations brought in $18.3M of cash; after $4.6M of capital spending, free cash flow was $13.7M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Mannkind Corp's next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Mannkind Corp does
Mannkind Corp is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MNKD.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $349M | $5.9M | $0.02 | $13.7M |
| 2024 | $285.5M | $27.6M | $0.10 | $32.8M |
| 2023 | $199M | -$11.9M | -$0.04 | -$8.3M |
| 2022 | $99.8M | -$87.4M | -$0.34 | -$88.3M |
| 2021 | $75.4M | -$80.9M | -$0.32 | -$73.2M |
| 2020 | $65.1M | -$57.2M | -$0.26 | -$28.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where MNKD ranks in Health care
Latest SEC filings
What Mannkind Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 24% to $101.9M versus the same quarter last year; diluted EPS -$0.07 versus $0.03.
- November 5, 2026
- August 21, 2026Other event 8-K
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 43% to $109.4M versus the same quarter last year; diluted EPS -$0.06 versus $0.00.
- August 5, 2026
- July 31, 2026Passive stake (5% or more) SCHEDULE 13G
- July 24, 2026
- June 2, 2026Other event 8-K
- May 28, 2026Other event 8-K
What is MNKD worth? A DCF from its reported cash flow
Insider trades
What the people running Mannkind Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $256.3K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 25, 2026 | Binder Steven B.Director | Soldpre-planned (10b5-1) | 39,051 | $128.5K |
| September 10, 2026 | Binder Steven B.Director | Soldpre-planned (10b5-1) | 33,558 | $127.9K |
| August 7, 2026 | Binder Steven B.Director | Soldpre-planned (10b5-1) | 39,051 | $158.5K |
| July 17, 2026 | Binder Steven B.Director | Soldpre-planned (10b5-1) | 52,485 | $213.1K |
| July 17, 2026 | Thomson DavidEVP Genl Counsel & Secretary | Soldpre-planned (10b5-1) | 24,109 | $97.6K |
| July 15, 2026 | Binder Steven B.Director | Exercised options | 93,790 | - |
| July 15, 2026 | Binder Steven B.Director | Shares withheld for tax | 15,688 | $64.2K |
| July 15, 2026 | Binder Steven B.Director | Shares withheld for tax | 4,073 | $16.7K |
Who owns MNKD
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Rubric Capital Management LP13G, passive with 1 related filers | 5.83% | August 14, 2026 |
| Vanguard Capital Management13G, passive | 5% | July 31, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 259 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 32,133,223 | +3,532,225 |
| Rubric Capital Management LP | 18,000,000 | +14,379,587 |
| State Street Corp | 16,174,043 | -2,509,440 |
| Vanguard Capital Management LLC | 13,169,392 | +278,326 |
| Geode Capital Management, LLC | 7,947,203 | +442,056 |
| Wellington Management Group Llp | 7,844,807 | +4,561,628 |
| Frazier Life Sciences Management, L.P. | 6,600,000 | +700,000 |
| Deep Track Capital, LP | 6,000,000 | new |
| 180 Wealth Advisors, LLC | 4,959,351 | +667,648 |
| Fmr LLC | 4,101,046 | +620,082 |
| TSP Capital Management Group, LLC | 3,972,675 | new |
| Aqr Capital Management LLC | 3,808,824 | +3,355,838 |
| Morgan Stanley | 3,474,870 | -2,318,277 |
| Braidwell LP | 3,458,429 | new |
| Vanguard Portfolio Management LLC | 3,002,169 | -169,655 |
| Northern Trust Corp | 2,887,290 | +211,340 |
| UBS Group AG | 2,886,231 | -5,369,199 |
| Two Sigma Investments, LP | 2,693,712 | -202,162 |
| Charles Schwab Investment Management Inc | 2,598,727 | +49,660 |
| Bank of America Corp | 2,364,872 | -1,018,805 |
Insiders
11 insiders reported holding 6,895,095 shares in total, about $28.9M at the last price.
| Holder | Shares |
|---|---|
| Castagna MichaelChief Executive Officer, Director | 2,433,779 |
| Tross Stuart AChief People & Workpl Officer | 1,058,142 |
| Thomson DavidEVP Genl Counsel & Secretary | 797,554 |
| Binder Steven B.Director | 713,258 |
| Singh Sanjay REVP Technical Operations | 478,966 |
| Marasco DominicPres, Endocrine Business Unit | 343,398 |
| Prentiss Christopher BChief Financial Officer | 318,668 |
| Ahuja AjayChief Medical Officer | 318,200 |
| Hooper Anthony CDirector | 236,153 |
| Consiglio Ronald JDirector | 132,342 |
Questions about MNKD
What does Mannkind Corp do?
Mannkind Corp is a company in the Health care sector, listed on NASDAQ as MNKD. Its shares trade on NASDAQ under the ticker MNKD.
What is Mannkind Corp's net worth?
Mannkind Corp has a market value (market cap) of $1.3B at the latest share price, and shareholders' equity of -$37.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Mannkind Corp profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $74.8M on revenue of $413.4M.
How much revenue does Mannkind Corp make?
Over the twelve months to September 30, 2026 Mannkind Corp reported revenue of $413.4M. That is 31.7% more than a year earlier.
When did Mannkind Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Mannkind Corp's next earnings report?
Mannkind Corp's next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare MNKD with
Follow MNKD
Get an email when Mannkind Corp files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Mannkind Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.